

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



MicroPort CardioFlow Medtech Corporation

微创心通医疗科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2160)

VOLUNTARY ANNOUNCEMENT

CE MARK APPROVAL OF ANCHORMAN® LAAC SYSTEM AND ITS ACCESS SYSTEM

This announcement is made by MicroPort CardioFlow Medtech Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement and product development progress of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that AnchorMan® left atrial appendage (the “**LAA**”) closure system (the “**AnchorMan® LAAC System**”) and its access system (“**AnchorMan® LAAA System**”) received CE Mark (certification mark that indicates conformity with health, safety and environmental protection standards for products sold within the European Economic Area) approval.

AnchorMan® LAAC System and AnchorMan® LAAA System are both self-developed products of Shanghai MicroPort CardioAdvent Co., Ltd. (上海佐心醫療科技有限公司) (“**MP CardioAdvent**”), a subsidiary of the Company. AnchorMan® LAAC System is intended for percutaneous, transcatheter closure of the LAA to prevent thrombus embolization from the LAA. AnchorMan® LAAA System is compatible with AnchorMan® LAAC System to provide the femoral venous and trans-atrial septal access. AnchorMan® LAAC System and AnchorMan® LAAA System have both received approval from the National Medical Products Administration of the People’s Republic of China (國家藥品監督管理局). AnchorMan® LAAC System is the only approved semi-closed type LAAC product in China so far.

The CE Mark approvals of both AnchorMan® LAAC System and AnchorMan® LAAA System signify that their innovative R&D (research and development) design and excellent clinical performance have reached the international level, offering prerequisite for them to enter into the structural heart disease field in the European market, and also providing strong support for their expansion to more overseas markets, which is an important milestone in the Company's development progress and global strategic layout. The Company's revenue stream is then expected to be further enhanced and so does its global comprehensive competitiveness, which offers the Company with more opportunities in the international market to benefit more structural heart disease patients.

By order of the Board
MicroPort CardioFlow Medtech Corporation
Chen Guoming
Chairman

Shanghai, PRC, February 21, 2025

As of the date of this announcement, the executive Directors are Mr. Jeffrey R Lindstrom, Mr. Zhao Liang and Ms. Yan Luying, the non-executive Directors are Mr. Chen Guoming, Mr. Zhang Junjie and Ms. Wu Xia, and the independent non-executive Directors are Mr. Jonathan H. Chou, Dr. Ding Jiandong and Ms. Sun Zhixiang.